View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 18, 2011

BioMarin Initiates BMN 673 Drug Trial

BioMarin Pharmaceutical has initiated a Phase I trial of a once-daily, oral poly-ADP-ribose polymerase inhibitor in patients with advanced haematological malignancies. The two-arm, open-label dose escalation study of the drug, known as BMN 673, will involve around 80 patients across mu

By cms admin

BioMarin Pharmaceutical has initiated a Phase I trial of a once-daily, oral poly-ADP-ribose polymerase inhibitor in patients with advanced haematological malignancies.

The two-arm, open-label dose escalation study of the drug, known as BMN 673, will involve around 80 patients across multiple sites in the US and the UK.

The study is intended to evaluate the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the drug in patients with acute myeloid leukemia, myelodysplastic syndrome, chronic lymphocytic leukemia or mantle cell lymphoma.

BioMarin Pharmaceutical chief medical officer Hank Fuchs said the approach to the development of the poly-ADP-ribose polymerase inhibitor is to identify tumour mutations that are more susceptible to treatment with BMN 673 and to target subgroups based on the genetic basis of the disease.

”We look forward to many clinical milestones over the next 18 months,” Fuchs added.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology